首页> 外国专利> therapeutic agent for dry eye comprising nandrolone or ester thereof or methenolone or ester thereof as an active ingredient

therapeutic agent for dry eye comprising nandrolone or ester thereof or methenolone or ester thereof as an active ingredient

机译:以诺龙或其酯或甲烯龙或其酯为有效成分的干眼症治疗剂

摘要

An object of the present invention is to provide a novel dry eye therapeutic agent that demonstrates superior dry eye therapeutic effects, and from the viewpoint of the drug administration burden of the patient, is capable of demonstrating a medicinal effect over a long period of time in lacrimal gland tissue after the administration thereof. A dry eye therapeutic agent comprising nandrolone or an ester thereof or methenolone or an ester thereof is therapeutically effective on dry eye since it increases the amount of tear lipocalin (TL) in tears, and medicinal effects can be demonstrated over a long period of time in lacrimal gland tissue by administering a dry eye therapeutic agent comprising nandrolone or an ester thereof or methenolone or an ester thereof to eyelid skin.
机译:本发明的目的是提供一种新型的干眼治疗剂,该干眼治疗剂显示出优异的干眼治疗效果,并且从患者的药物给药负担的观点出发,能够长期显示出药效。给药后的泪腺组织。包含nandrolone或其酯或methenolone或其酯的干眼治疗剂对干眼有治疗效果,因为它增加了眼泪中泪脂钙蛋白(TL)的量,并且可以在很长一段时间内证明其药物作用。通过向眼睑皮肤施用包含诺龙或其酯或美乃龙酮或其酯的干眼治疗剂来泪腺组织。

著录项

  • 公开/公告号BR112017021044A2

    专利类型

  • 公开/公告日2018-07-24

    原文格式PDF

  • 申请/专利权人 SANTEN PHARMACEUTICAL CO. LTD.;

    申请/专利号BR20171121044

  • 发明设计人 KENICHI ENDO;KENJI OKI;SHINOBU FUJII;

    申请日2016-04-01

  • 分类号A61K9/06;A61K31/568;A61P27/02;

  • 国家 BR

  • 入库时间 2022-08-21 12:53:41

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号